Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 17/20 | 0.72 |
| ▸ | MTOR | P42345 | 11/20 | 0.64 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.64 |
| ▸ | PIK3CG | P48736 | 6/20 | 0.59 |
| ▸ | ATR | Q13535 | 1/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.49 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29183837 | 0.88 | PIK3CA (0.67) | PIK3CAMTORPIK3R1PIK3CGATR | |
| SCHEMBL30805549 | 0.88 | PIK3CA (0.67) | PIK3CAMTORPIK3R1PIK3CGATR | |
| SCHEMBL18660598 | 0.87 | PIK3CA (0.57) | PIK3CAMTORPIK3R1PIK3CGATR | |
| SCHEMBL29184013 | 0.86 | PIK3CA (0.65) | PIK3CAMTORPIK3R1 | |
| SCHEMBL1409203 | 0.86 | PIK3CA (0.57) | PIK3CAMTORPIK3R1PIK3CGATR | |
| SCHEMBL1409215 | 0.85 | PIK3CA (0.54) | PIK3CAMTORPIK3R1PIK3CGATR | |
| SCHEMBL28606405 | 0.84 | PIK3CA (1.00) | PIK3CAMTORPIK3CG | |
| SCHEMBL28601878 | 0.83 | PIK3CA (1.00) | PIK3CAMTORPIK3R1PIK3CGATR | |
| SCHEMBL910378 | 0.82 | PIK3CA (0.66) | PIK3CAMTORPIK3R1 | |
| SCHEMBL1409540 | 0.82 | PIK3CA (0.54) | PIK3CAMTORPIK3R1PIK3CGATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117777042-B | Triazine hydroxamic acid derivative and preparation method and application thereof | 长沙医学院 | 2025-01-24 | — | — | CN | disclosed |
| CN-117777042-A | Triazine hydroxamic acid derivative and preparation method and application thereof | 长沙医学院 | 2024-03-29 | — | — | CN | disclosed |
| EP-3481822-B1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND MTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2022-06-22 | — | — | EP | disclosed |
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-02-16 | — | — | US | disclosed |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10919877-B2 | Multifunctional inhibitors of MEK/PI3K and mTOR/MEK/PI3K biological pathways and therapeutic methods using the same | MTOR, PIK3CA, MAPKAP1 | PIK3CA 2/4885MTOR 1/4885PIK3R1 7/4885 |
| US-20190224207-A1 | MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME | MTOR, PIK3CA, MAPKAP1 | PIK3CA 2/4885MTOR 1/4885PIK3R1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.